49,277
edits
Difference between revisions of "Polymorphous adenocarcinoma"
Jump to navigation
Jump to search
no edit summary
| (6 intermediate revisions by the same user not shown) | |||
| Line 9: | Line 9: | ||
| LMDDx = [[adenoid cystic carcinoma]], [[pleomorphic adenoma]], [[cribriform adenocarcinoma of the minor salivary gland]] | | LMDDx = [[adenoid cystic carcinoma]], [[pleomorphic adenoma]], [[cribriform adenocarcinoma of the minor salivary gland]] | ||
| Stains = | | Stains = | ||
| IHC = S-100 +ve, CK7 | | IHC = S-100 +ve, CK7 +ve, p40 -ve, p63 +ve, vimentin +ve | ||
| EM = | | EM = | ||
| Molecular = | | Molecular = | ||
| Line 54: | Line 54: | ||
Note: | Note: | ||
*'' | *''Pretty much always'' a low-grade tumour. | ||
DDx: | DDx: | ||
*[[Adenoid cystic carcinoma]]. | *[[Adenoid cystic carcinoma]]. | ||
*[[Pleomorphic adenoma]]. | *[[Pleomorphic adenoma]]. | ||
*[[Cribriform adenocarcinoma of the minor salivary gland]].<ref name= | *[[Cribriform adenocarcinoma of the minor salivary gland]] - if one considers it a separate diagnosis. | ||
</ref> | **The ''World Health Organization'' lumps ''[[cribriform adenocarcinoma of the minor salivary gland]]'' with ''polymorphous adenocarcinoma''.<ref name=pmid29761209>{{cite journal |authors=Vander Poorten V, Triantafyllou A, Skálová A, Stenman G, Bishop JA, Hauben E, Hunt JL, Hellquist H, Feys S, De Bree R, Mäkitie AA, Quer M, Strojan P, Guntinas-Lichius O, Rinaldo A, Ferlito A |title=Polymorphous adenocarcinoma of the salivary glands: reappraisal and update |journal=Eur Arch Otorhinolaryngol |volume=275 |issue=7 |pages=1681–1695 |date=July 2018 |pmid=29761209 |doi=10.1007/s00405-018-4985-5 |url=}}</ref> | ||
===Images=== | ===Images=== | ||
<gallery> | <gallery> | ||
| Line 75: | Line 74: | ||
*p63 +ve (22 of 23 cases<ref name=pmid31653135/>). | *p63 +ve (22 of 23 cases<ref name=pmid31653135/>). | ||
*p40 -ve (22 of 23 cases<ref name=pmid31653135>{{cite journal |authors=Atiq A, Mushtaq S, Hassan U, Loya A, Hussain M, Akhter N |title=Utility of p63 and p40 in Distinguishing Polymorphous Adenocarcinoma and Adenoid Cystic Carcinoma |journal=Asian Pac J Cancer Prev |volume=20 |issue=10 |pages=2917–2921 |date=October 2019 |pmid=31653135 |pmc=6982655 |doi=10.31557/APJCP.2019.20.10.2917 |url=}}</ref>). | *p40 -ve (22 of 23 cases<ref name=pmid31653135>{{cite journal |authors=Atiq A, Mushtaq S, Hassan U, Loya A, Hussain M, Akhter N |title=Utility of p63 and p40 in Distinguishing Polymorphous Adenocarcinoma and Adenoid Cystic Carcinoma |journal=Asian Pac J Cancer Prev |volume=20 |issue=10 |pages=2917–2921 |date=October 2019 |pmid=31653135 |pmc=6982655 |doi=10.31557/APJCP.2019.20.10.2917 |url=}}</ref>). | ||
**Useful to differentiate from [[adenoid cystic carcinoma]] (AdCC); AdCC is usually p63 +ve/p40 +ve (36 | **Useful to differentiate from [[adenoid cystic carcinoma]] (AdCC); AdCC is usually p63 +ve/p40 +ve (36 of 47 cases) or p63 -ve/p40 -ve (10 of 47 cases). | ||
***p63 +ve/p40 +ve is seen in pleomorphic adenoma and mucoepidermoid carcinoma (in addition to adenoid cystic carcinoma).<ref name=pmid34518135>{{cite journal |authors=Sivakumar N, Narwal A, Pandiar D, Devi A, Anand R, Bansal D, Kamboj M |title=Diagnostic utility of p63/p40 in the histologic differentiation of salivary gland tumors: A systematic review |journal=Oral Surg Oral Med Oral Pathol Oral Radiol |volume=133 |issue=2 |pages=189–198 |date=February 2022 |pmid=34518135 |doi=10.1016/j.oooo.2021.07.010 |url=}}</ref> | |||
Others: | Others: | ||
| Line 87: | Line 87: | ||
==References== | ==References== | ||
{{Reflist| | {{Reflist|2}} | ||
[[Category:Diagnosis]] | [[Category:Diagnosis]] | ||
[[Category:Salivary gland]] | [[Category:Salivary gland]] | ||